Vertex lifts revenue guidance as cystic fibrosis franchise drives strong second quarter
Vertex Pharmaceuticals (VRTX) raised the upper end of its full-year revenue forecast, citing robust demand across its cystic fibrosis portfolio after second-quarter sales came in ahead of Wall Street expectations.
